We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
CALTX.ST

Price
-
Stock movement up
+1.80 (0.87%)
Company name
Calliditas Therapeutics
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Biotechnology
Market cap
11.24B
Ent value
12.08B
Price/Sales
7.02
Price/Book
105.24
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
15.46
PEG
-
EPS growth
18.29%
1 year return
109.78%
3 year return
30.22%
5 year return
30.48%
10 year return
-
Last updated: 2024-12-17

DIVIDENDS

CALTX.ST does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA247.08
EV to EBITDA265.62

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales7.02
Price to Book105.24
EV to Sales7.54

FINANCIALS

Per share

Loading...
Per share data
Current share count54.03M
EPS (TTM)-8.95
FCF per share (TTM)-4.93

Income statement

Loading...
Income statement data
Revenue (TTM)1.60B
Gross profit (TTM)1.50B
Operating income (TTM)-368.18M
Net income (TTM)-480.36M
EPS (TTM)-8.95
EPS (1y forward)13.45

Margins

Loading...
Margins data
Gross margin (TTM)93.46%
Operating margin (TTM)-22.99%
Profit margin (TTM)-30.00%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash797.28M
Net receivables222.59M
Total current assets1.15B
Goodwill47.81M
Intangible assets423.86M
Property, plant and equipment59.36M
Total assets1.75B
Accounts payable151.01M
Short/Current long term debt1.01B
Total current liabilities429.78M
Total liabilities1.64B
Shareholder's equity106.79M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-244.93M
Capital expenditures (TTM)19.83M
Free cash flow (TTM)-264.76M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-449.82%
Return on Assets-27.49%
Return on Invested Capital-44.10%
Cash Return on Invested Capital-24.31%

STOCK INFORMATION

Downside potential

Loading...
Downside potential data
CALTX.STS&P500
Current price drop from All-time high-0.10%-0.17%
Highest price drop-58.42%-56.47%
Date of highest drop9 May 20229 Mar 2009
Avg drop from high-24.08%-11.07%
Avg time to new high41 days12 days
Max time to new high881 days1805 days
COMPANY DETAILS
CALTX.ST (Calliditas Therapeutics) company logo
Marketcap
11.24B
Marketcap category
Large-cap
Description
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.
Employees
222
Investor relations
-
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found